49 Wealth Management LLC purchased a new position in shares of Danaher Co. (NYSE:DHR – Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 930 shares of the conglomerate’s stock, valued at approximately $259,000.
A number of other institutional investors also recently bought and sold shares of DHR. Swedbank AB purchased a new stake in shares of Danaher in the 1st quarter valued at about $676,545,000. TD Asset Management Inc increased its position in Danaher by 99.0% in the 2nd quarter. TD Asset Management Inc now owns 1,358,706 shares of the conglomerate’s stock valued at $339,473,000 after acquiring an additional 675,952 shares during the period. Massachusetts Financial Services Co. MA increased its position in Danaher by 22.7% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 3,047,728 shares of the conglomerate’s stock valued at $761,475,000 after acquiring an additional 563,546 shares during the period. International Assets Investment Management LLC increased its position in Danaher by 40,196.5% in the 3rd quarter. International Assets Investment Management LLC now owns 429,964 shares of the conglomerate’s stock valued at $119,539,000 after acquiring an additional 428,897 shares during the period. Finally, B. Metzler seel. Sohn & Co. Holding AG acquired a new position in Danaher in the 3rd quarter valued at about $77,314,000. 79.05% of the stock is owned by hedge funds and other institutional investors.
Insider Activity at Danaher
In other Danaher news, SVP Georgeann Couchara sold 952 shares of the stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the transaction, the senior vice president now owns 4,212 shares of the company’s stock, valued at $1,130,374.44. This represents a 18.44 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. 11.10% of the stock is owned by corporate insiders.
Analyst Ratings Changes
View Our Latest Stock Report on DHR
Danaher Price Performance
Shares of NYSE:DHR opened at $235.83 on Friday. The business’s 50 day simple moving average is $258.15 and its 200-day simple moving average is $259.88. The firm has a market capitalization of $170.33 billion, a price-to-earnings ratio of 45.01, a price-to-earnings-growth ratio of 4.25 and a beta of 0.85. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. Danaher Co. has a 12 month low of $215.68 and a 12 month high of $281.70.
Danaher (NYSE:DHR – Get Free Report) last posted its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The firm had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same quarter in the prior year, the company earned $2.02 EPS. Danaher’s revenue was up 3.1% on a year-over-year basis. As a group, equities analysts forecast that Danaher Co. will post 7.5 earnings per share for the current fiscal year.
Danaher Dividend Announcement
The business also recently announced a quarterly dividend, which was paid on Friday, October 25th. Investors of record on Friday, September 27th were paid a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.46%. The ex-dividend date was Friday, September 27th. Danaher’s payout ratio is currently 20.61%.
Danaher Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Further Reading
- Five stocks we like better than Danaher
- 3 Small Caps With Big Return Potential
- Tesla Investors Continue to Profit From the Trump Trade
- What Do S&P 500 Stocks Tell Investors About the Market?
- MicroStrategy’s Stock Dip vs. Coinbase’s Potential Rally
- Using the MarketBeat Dividend Tax Calculator
- Netflix Ventures Into Live Sports, Driving Stock Momentum
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.